$INNT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in 9 METERS BIOPHARMA, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in 9 METERS BIOPHARMA, INC.. Get notifications about new insider transactions in 9 METERS BIOPHARMA, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 2021 | INNT | 9 METERS BIOPHARMA ... | OrbiMed Israel GP Ltd. | 10% Owner | Option Exercise | X | 0.62 | 19,444 | 12,086 | 80,556 | |
| May 13 2021 | INNT | 9 METERS BIOPHARMA ... | OrbiMed Israel GP Ltd. | 10% Owner | Option Exercise | X | 0.70 | 12,500 | 8,750 | 37,500 | |
| May 13 2021 | INNT | 9 METERS BIOPHARMA ... | OrbiMed Israel GP Ltd. | 10% Owner | Buy | X | 0.62 | 19,444 | 12,086 | 25,748,699 | 25.7 M to 25.7 M (+0.08 %) |
| May 13 2021 | INNT | 9 METERS BIOPHARMA ... | OrbiMed Israel GP Ltd. | 10% Owner | Buy | X | 0.70 | 12,500 | 8,750 | 25,729,255 | 25.7 M to 25.7 M (+0.05 %) |
| Apr 06 2021 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 1.00 | 300,000 | 300,000 | 1,074,066 | 774.1 K to 1.1 M (+38.76 %) |
| Apr 06 2021 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | P | 1.00 | 100,000 | 100,000 | 1,077,522 | 977.5 K to 1.1 M (+10.23 %) |
| Apr 06 2021 | INNT | 9 METERS BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Buy | P | 1.00 | 50,000 | 50,000 | 179,338 | 129.3 K to 179.3 K (+38.66 %) |
| Dec 17 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | P | 0.65 | 153,846 | 100,000 | 977,522 | 823.7 K to 977.5 K (+18.68 %) |
| Dec 17 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 0.65 | 230,769 | 150,000 | 774,066 | 543.3 K to 774.1 K (+42.48 %) |
| Dec 17 2020 | INNT | 9 METERS BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Buy | P | 0.65 | 61,538 | 40,000 | 129,338 | 67.8 K to 129.3 K (+90.76 %) |
| Dec 01 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | J | 1.07 | 639,655 | 684,431 | 639,655 | |
| Dec 01 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | J | 1.07 | 650,000 | 695,500 | 650,000 | |
| Dec 01 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | J | 0.62 | 639,655 | 397,610 | 310,345 | |
| Dec 01 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | J | 0.62 | 650,000 | 404,040 | 0 | |
| Dec 01 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Grant | A | 0.00 | 203,667 | 0 | 823,676 | 620 K to 823.7 K (+32.85 %) |
| Nov 03 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | J | 0.00 | 4,513 | 0 | 543,297 | 538.8 K to 543.3 K (+0.84 %) |
| Nov 03 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | J | 0.00 | 4,513 | 0 | 620,009 | 615.5 K to 620 K (+0.73 %) |
| Sep 14 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 0.65 | 21,485 | 14,004 | 21,485 | 0 to 21.5 K |
| Sep 14 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 0.68 | 77,000 | 52,360 | 538,784 | 461.8 K to 538.8 K (+16.67 %) |
| Sep 14 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 0.60 | 50,000 | 30,000 | 461,784 | 411.8 K to 461.8 K (+12.14 %) |
| Aug 24 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | P | 0.69 | 70,000 | 48,300 | 615,496 | 545.5 K to 615.5 K (+12.83 %) |
| Aug 21 2020 | INNT | 9 METERS BIOPHARMA ... | Constantino Michael T. | Director | Buy | P | 0.75 | 34,108 | 25,581 | 34,108 | 0 to 34.1 K |
| Aug 18 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 0.56 | 100,000 | 56,000 | 411,784 | 311.8 K to 411.8 K (+32.07 %) |
| Aug 17 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | P | 0.57 | 35,000 | 19,831 | 545,496 | 510.5 K to 545.5 K (+6.86 %) |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | A | 0.62 | 650,000 | 404,040 | 1,600,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | A | 0.62 | 950,000 | 590,520 | 950,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Option Exercise | A | 0.62 | 100,000 | 62,160 | 100,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Laumas Sandeep | Director | Option Exercise | A | 0.62 | 150,000 | 93,240 | 150,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | A | 0.62 | 150,000 | 93,240 | 150,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | A | 0.62 | 225,000 | 139,860 | 775,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | A | 0.62 | 550,000 | 341,880 | 550,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Darvish Nissim | Director | Option Exercise | A | 0.62 | 100,000 | 62,160 | 100,000 | |
| Jul 08 2020 | INNT | 9 METERS BIOPHARMA ... | Constantino Michael T. | Director | Option Exercise | A | 0.62 | 150,000 | 93,240 | 150,000 | |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Laumas Sandeep | Director | Option Exercise | C | 0.00 | 424 | 0 | 0 | |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Laumas Sandeep | Director | Buy | C | 0.00 | 42,400 | 0 | 60,400 | 18 K to 60.4 K (+235.56 %) |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | C | 0.00 | 678 | 0 | 0 | |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Buy | C | 0.00 | 67,800 | 0 | 67,800 | 0 to 67.8 K |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Option Exercise | C | 0.00 | 2,544 | 0 | 0 | |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | C | 0.00 | 254,400 | 0 | 311,784 | 57.4 K to 311.8 K (+443.33 %) |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | C | 0.00 | 848 | 0 | 0 | |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | JOHNSON LORIN K | Director | Buy | C | 0.00 | 84,800 | 0 | 84,800 | 0 to 84.8 K |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | C | 0.00 | 2,714 | 0 | 0 | |
| Jul 02 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | C | 0.00 | 271,400 | 0 | 510,496 | 239.1 K to 510.5 K (+113.51 %) |
| Jul 01 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Grant | A | 0.00 | 189,655 | 0 | 239,096 | 49.4 K to 239.1 K (+383.60 %) |
| Jun 16 2020 | INNT | 9 METERS BIOPHARMA ... | Sirgo Mark A | Director | Buy | P | 0.60 | 17,943 | 10,721 | 57,384 | 39.4 K to 57.4 K (+45.49 %) |
| Jun 15 2020 | INNT | 9 METERS BIOPHARMA ... | Temperato John | Chief Executive Off ... | Buy | P | 0.60 | 10,000 | 5,971 | 49,441 | 39.4 K to 49.4 K (+25.35 %) |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Darvish Nissim | Director | Option Exercise | A | 0.70 | 50,000 | 35,000 | 50,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | OrbiMed Israel GP Ltd. | Director | Option Exercise | A | 0.70 | 50,000 | 35,000 | 50,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sirgo Mark A | Director | Option Exercise | P | 0.00 | 2,544 | 0 | 254,400 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sirgo Mark A | Director | Option Exercise | P | 0.00 | 2,544 | 0 | 254,400 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sirgo Mark A | Director | Option Exercise | A | 0.70 | 50,000 | 35,000 | 50,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | P | 0.00 | 2,714 | 0 | 271,400 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | P | 0.00 | 2,714 | 0 | 271,400 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Temperato John | Chief Executive Off ... | Option Exercise | A | 0.70 | 1,000,000 | 700,000 | 1,000,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | P | 0.00 | 848 | 0 | 84,800 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | P | 0.00 | 848 | 0 | 84,800 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Director | Option Exercise | P | 0.00 | 424 | 0 | 42,400 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Director | Option Exercise | P | 0.00 | 424 | 0 | 42,400 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | P | 0.00 | 678 | 0 | 67,800 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | P | 0.00 | 678 | 0 | 67,800 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Proujansky Roy | Director | Option Exercise | A | 0.60 | 25,000 | 15,000 | 25,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | A | 0.60 | 25,000 | 15,000 | 25,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Director | Option Exercise | A | 0.60 | 389,294 | 233,576 | 389,294 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | A | 0.70 | 125,000 | 87,500 | 125,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | A | 0.60 | 176,156 | 105,694 | 176,156 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | MAIDA ANTHONY E III | Director | Option Exercise | A | 0.60 | 25,000 | 15,000 | 25,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Ramasastry Saira | Director | Option Exercise | A | 0.60 | 25,000 | 15,000 | 25,000 | |
| May 04 2020 | INNT | INNOVATE BIOPHARMA ... | Madan Jay P. | President | Option Exercise | A | 0.60 | 203,406 | 122,044 | 203,406 | |
| Aug 27 2019 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | CEO, Executive Chai ... | Option Exercise | A | 0.89 | 400,000 | 356,000 | 400,000 | |
| Aug 27 2019 | INNT | INNOVATE BIOPHARMA ... | Madan Jay P. | President | Option Exercise | A | 0.89 | 200,000 | 178,000 | 200,000 | |
| Jul 03 2019 | INNT | INNOVATE BIOPHARMA ... | Sitar Edward J | Chief Financial Off ... | Option Exercise | A | 1.17 | 350,000 | 409,500 | 350,000 | |
| Jul 01 2019 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | CEO, Executive Chai ... | Buy | P | 1.15 | 4,000 | 4,600 | 18,000 | 14 K to 18 K (+28.57 %) |
| Jun 17 2019 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | CEO, Executive Chai ... | Buy | P | 1.22 | 591 | 721 | 14,000 | 13.4 K to 14 K (+4.41 %) |
| Jun 17 2019 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | CEO, Executive Chai ... | Buy | P | 1.21 | 409 | 495 | 13,409 | 13 K to 13.4 K (+3.15 %) |
| Jun 04 2019 | INNT | INNOVATE BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | A | 1.28 | 25,000 | 32,000 | 25,000 | |
| Jun 04 2019 | INNT | INNOVATE BIOPHARMA ... | MAIDA ANTHONY E III | Director | Option Exercise | A | 1.28 | 25,000 | 32,000 | 25,000 | |
| Jun 04 2019 | INNT | INNOVATE BIOPHARMA ... | Ramasastry Saira | Director | Option Exercise | A | 1.28 | 25,000 | 32,000 | 25,000 | |
| Jun 04 2019 | INNT | INNOVATE BIOPHARMA ... | Proujansky Roy | Director | Option Exercise | A | 1.28 | 25,000 | 32,000 | 25,000 | |
| Jun 03 2019 | INNT | INNOVATE BIOPHARMA ... | Madan Jay P. | President | Buy | P | 1.32 | 5,000 | 6,600 | 84,131 | 79.1 K to 84.1 K (+6.32 %) |
| May 28 2019 | INNT | INNOVATE BIOPHARMA ... | Proujansky Roy | Director | Buy | P | 1.28 | 1,000 | 1,280 | 2,400 | 1.4 K to 2.4 K (+71.43 %) |
| May 23 2019 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | CEO, Executive Chai ... | Buy | P | 1.38 | 5,000 | 6,900 | 13,000 | 8 K to 13 K (+62.50 %) |
| Dec 07 2018 | INNT | INNOVATE BIOPHARMA ... | MAIDA ANTHONY E III | Director | Option Exercise | A | 2.41 | 25,000 | 60,250 | 25,000 | |
| Dec 07 2018 | INNT | INNOVATE BIOPHARMA ... | JOHNSON LORIN K | Director | Option Exercise | A | 2.41 | 25,000 | 60,250 | 25,000 | |
| Dec 07 2018 | INNT | INNOVATE BIOPHARMA ... | Proujansky Roy | Director | Option Exercise | A | 2.41 | 25,000 | 60,250 | 25,000 | |
| Dec 07 2018 | INNT | INNOVATE BIOPHARMA ... | Proujansky Roy | Director | Option Exercise | A | 6.94 | 50,000 | 347,000 | 50,000 | |
| Dec 07 2018 | INNT | INNOVATE BIOPHARMA ... | Ramasastry Saira | Director | Option Exercise | A | 2.41 | 25,000 | 60,250 | 25,000 | |
| Dec 07 2018 | INNT | INNOVATE BIOPHARMA ... | Ramasastry Saira | Director | Option Exercise | A | 6.94 | 50,000 | 347,000 | 50,000 | |
| Dec 03 2018 | INNT | INNOVATE BIOPHARMA ... | Proujansky Roy | Director | Buy | P | 2.63 | 1,400 | 3,682 | 1,400 | 0 to 1.4 K |
| Dec 03 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 2.63 | 1,000 | 2,630 | 8,000 | 7 K to 8 K (+14.29 %) |
| Dec 03 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 2.62 | 1,000 | 2,620 | 7,000 | 6 K to 7 K (+16.67 %) |
| Dec 03 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 2.64 | 1,000 | 2,640 | 6,000 | 5 K to 6 K (+20.00 %) |
| Nov 29 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 2.56 | 2,000 | 5,120 | 5,000 | 3 K to 5 K (+66.67 %) |
| Nov 29 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 2.55 | 1,000 | 2,550 | 3,000 | 2 K to 3 K (+50.00 %) |
| Nov 29 2018 | INNT | INNOVATE BIOPHARMA ... | Prior Christopher P. | Chief Executive Off ... | Buy | P | 2.75 | 5,000 | 13,750 | 7,009 | 2 K to 7 K (+248.88 %) |
| Sep 14 2018 | INNT | INNOVATE BIOPHARMA ... | Prior Christopher P. | Chief Executive Off ... | Buy | P | 5.82 | 200 | 1,164 | 2,009 | 1.8 K to 2 K (+11.06 %) |
| Sep 13 2018 | INNT | INNOVATE BIOPHARMA ... | Prior Christopher P. | Chief Executive Off ... | Buy | P | 6.13 | 500 | 3,065 | 1,809 | 1.3 K to 1.8 K (+38.20 %) |
| Sep 10 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 6.10 | 500 | 3,050 | 2,000 | 1.5 K to 2 K (+33.33 %) |
| Aug 30 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 5.24 | 500 | 2,620 | 750 | 250 to 750 (+200.00 %) |
| Aug 30 2018 | INNT | INNOVATE BIOPHARMA ... | Prior Christopher P. | Chief Executive Off ... | Buy | P | 5.20 | 309 | 1,607 | 1,309 | 1,000 to 1.3 K (+30.90 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Prior Christopher P. | Chief Executive Off ... | Buy | P | 4.93 | 1,000 | 4,930 | 1,000 | 0 to 1,000 |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 5.08 | 405 | 2,057 | 1,000 | 595 to 1,000 (+68.07 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 5.07 | 95 | 482 | 595 | 500 to 595 (+19.00 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Laumas Sandeep | Executive Chairman | Buy | P | 4.88 | 250 | 1,220 | 500 | 250 to 500 (+100.00 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Almenoff June Sherie | COO and Chief Medic ... | Buy | P | 4.85 | 500 | 2,425 | 1,400 | 900 to 1.4 K (+55.56 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Almenoff June Sherie | COO and Chief Medic ... | Buy | P | 4.94 | 100 | 494 | 900 | 800 to 900 (+12.50 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Almenoff June Sherie | COO and Chief Medic ... | Buy | P | 4.96 | 253 | 1,255 | 800 | 547 to 800 (+46.25 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Almenoff June Sherie | COO and Chief Medic ... | Buy | P | 4.90 | 47 | 230 | 547 | 500 to 547 (+9.40 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Almenoff June Sherie | COO and Chief Medic ... | Buy | P | 4.99 | 400 | 1,996 | 500 | 100 to 500 (+400.00 %) |
| Aug 28 2018 | INNT | INNOVATE BIOPHARMA ... | Almenoff June Sherie | COO and Chief Medic ... | Buy | P | 4.85 | 100 | 485 | 100 | 0 to 100 |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Buy | P | 0.35 | 300,000 | 105,000 | 1,718,450 | 1.4 M to 1.7 M (+21.15 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Grant | A | 0.00 | 25,000 | 0 | 1,418,450 | 1.4 M to 1.4 M (+1.79 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Grant | A | 0.00 | 17,746 | 0 | 1,393,450 | 1.4 M to 1.4 M (+1.29 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Buy | P | 0.45 | 366,159 | 164,772 | 1,375,704 | 1 M to 1.4 M (+36.27 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Grant | A | 0.00 | 100,000 | 0 | 1,009,545 | 909.5 K to 1 M (+10.99 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Grant | A | 0.00 | 13,467 | 0 | 909,545 | 896.1 K to 909.5 K (+1.50 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Grant | A | 0.00 | 33,621 | 0 | 896,078 | 862.5 K to 896.1 K (+3.90 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Buy | P | 0.58 | 172,414 | 100,000 | 862,457 | 690 K to 862.5 K (+24.99 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Buy | P | 1.50 | 70,000 | 105,000 | 690,043 | 620 K to 690 K (+11.29 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Grant | A | 0.00 | 175,000 | 0 | 620,043 | 445 K to 620 K (+39.32 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARKE DAVID H | Former CEO and Dire ... | Buy | P | 4.50 | 15,000 | 67,500 | 445,043 | 430 K to 445 K (+3.49 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | Olert David Lewis | Former CFO | Grant | A | 0.00 | 10,000 | 0 | 70,000 | 60 K to 70 K (+16.67 %) |
| Mar 13 2018 | MSDI | INNOVATE BIOPHARMA ... | CLARK JONATHAN P | Former Interim Pres ... | Grant | A | 0.00 | 10,000 | 0 | 285,000 | 275 K to 285 K (+3.64 %) |
| Nov 21 2017 | MSDI | Monster Digital, I ... | Olert David Lewis | CFO | Grant | A | 0.00 | 10,000 | 0 | 60,000 | 50 K to 60 K (+20.00 %) |
| Nov 21 2017 | MSDI | Monster Digital, I ... | CLARK JONATHAN P | Interim President | Grant | A | 0.00 | 25,000 | 0 | 275,000 | 250 K to 275 K (+10.00 %) |
| Nov 21 2017 | MSDI | Monster Digital, I ... | BARRE STEVEN C | Director | Grant | A | 0.00 | 10,000 | 0 | 50,000 | 40 K to 50 K (+25.00 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | Olert David Lewis | CFO | Grant | A | 0.00 | 10,000 | 0 | 50,000 | 40 K to 50 K (+25.00 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | BARRE STEVEN C | Director | Grant | A | 0.00 | 10,000 | 0 | 40,000 | 30 K to 40 K (+33.33 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | BARRE STEVEN C | Director | Grant | A | 0.00 | 15,000 | 0 | 30,000 | 15 K to 30 K (+100.00 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | MINER CHRISTOPHER MICHAEL | Director | Grant | A | 0.00 | 10,000 | 0 | 35,000 | 25 K to 35 K (+40.00 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | MINER CHRISTOPHER MICHAEL | Director | Grant | A | 0.00 | 10,000 | 0 | 25,000 | 15 K to 25 K (+66.67 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | MACHINIST ROBERT | Director | Grant | A | 0.00 | 10,000 | 0 | 35,000 | 25 K to 35 K (+40.00 %) |
| Jul 13 2017 | MSDI | Monster Digital, I ... | MACHINIST ROBERT | Director | Grant | A | 0.00 | 10,000 | 0 | 25,000 | 15 K to 25 K (+66.67 %) |
| Jan 27 2017 | MSDI | Monster Digital, I ... | MACHINIST ROBERT | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
| Jan 26 2017 | MSDI | Monster Digital, I ... | MINER CHRISTOPHER MICHAEL | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
| Jan 26 2017 | MSDI | Monster Digital, I ... | CLARK JONATHAN P | Interim President | Grant | A | 0.00 | 240,000 | 0 | 250,000 | 10 K to 250 K (+2,400.00 %) |
| Jan 26 2017 | MSDI | Monster Digital, I ... | BARRE STEVEN C | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
| Jan 25 2017 | MSDI | Monster Digital, I ... | MATEJKA MARC S | VP - Operations | Grant | A | 0.00 | 15,000 | 0 | 40,000 | 25 K to 40 K (+60.00 %) |
| Jan 25 2017 | MSDI | Monster Digital, I ... | Olert David Lewis | CFO | Grant | A | 0.00 | 15,000 | 0 | 40,000 | 25 K to 40 K (+60.00 %) |
| Nov 18 2016 | MSDI | Monster Digital, I ... | BARRE STEVEN C | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Jul 27 2016 | MSDI | Monster Digital, I ... | CLARK JONATHAN P | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Jul 26 2016 | MSDI | Monster Digital, I ... | Olert David Lewis | CFO | Option Exercise | A | 4.50 | 16,834 | 75,753 | 16,834 | |
| Jul 26 2016 | MSDI | Monster Digital, I ... | Olert David Lewis | CFO | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jul 26 2016 | MSDI | Monster Digital, I ... | TANDON JAWAHAR | Chairman of the Boa ... | Option Exercise | A | 5.63 | 76,911 | 432,624 | 76,911 | |
| Jul 26 2016 | MSDI | Monster Digital, I ... | TANDON JAWAHAR | Chairman of the Boa ... | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jul 26 2016 | MSDI | Monster Digital, I ... | TANDON VIVEK | EVP - Operations | Option Exercise | A | 4.50 | 18,000 | 81,000 | 18,000 | |
| Jul 26 2016 | MSDI | Monster Digital, I ... | TANDON VIVEK | EVP - Operations | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jul 20 2016 | MSDI | Monster Digital, I ... | ORBAN JONATHAN S | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Jul 19 2016 | MSDI | Monster Digital, I ... | MATEJKA MARC S | VP - Operations | Option Exercise | A | 4.50 | 18,000 | 81,000 | 18,000 | |
| Jul 19 2016 | MSDI | Monster Digital, I ... | MATEJKA MARC S | VP - Operations | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jul 13 2016 | MSDI | Monster Digital, I ... | MACHINIST ROBERT | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |